Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement – "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Terence R. Flotte, M.D.		
2. Your Title: Provost, Dean and Professor UMass Chan Medical School/Vice President ASGCT		
3. The Entity(ies) You are Representing: American Society of Gene and Cell Therapy (ASGCT)		
4. Are you testifying on behalf of the Federal, or a State or local government entity? (If "Yes," skip Item 5 and Item 6.)	**Yes**	**No** X
5. Grants, Contracts, and Payments **a. Please list any <u>Federal grants or contracts</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2021</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.** SEE ATTACHED. **b. Please list any <u>contracts or payments originating with a foreign government</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2021</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.** NONE		
6. Are you a fiduciary (i.e., authorized to act on behalf of or for the benefit of) for any entity that has an interest in the subject matter of the hearing?	**Yes**	**No** **x**
7. Please attach your curriculum vitae to your completed disclosure form.		

Signature: _____ **Date:** ___**<u>02/26/24</u>**_____

GRANTS

Current

1. 2UL1TR001453-05A1 (Luzuriaga, PI) 6/30/2020-
NIH/NCATS 5/31/2025
University of Massachusetts Center for Clinical and Translational Science (Linked award)
The major goal of this project is to facilitate greater efficiency and productivity of University of Massachusetts investigators by enhancing engagement in clinical research, training a new generation of researchers, and building an academic home for moving laboratory discoveries into treatment for patients.
Role: CO-PI/CO-Director

2. National Institutes of Health/ NHLBISP01HL158506-02 8/9/2020-
(PI: Flotte TR) 7/31/2026
Title: Models and Gene Therapies for AAT Deficiency
Overall – Project Narrative in this project, we will develop new gene therapy drugs to treat genetic emphysema due to alpha-1 antitrypsin deficiency (AATD), a common genetic disease and form of chronic obstructive pulmonary disease (COPD). In the Proposal, we will use advanced gene editing tools to create genetically defined animal models of AATD (known as transgenic animals), both in mice and in ferrets, which are a good model to study lung diseases. In the course of the study we will use the most cutting-edge tools in gene therapy, gene editing, and immune modulation to treat AATD in both animal models and determine the best ways to measure the success of gene therapy over time.
$1,669,445 Direct Costs/year ($2,676,698 Total Costs/Year)